News
India is among the top two countries in terms of type 2 diabetes cases and third in terms of obesity; hence, the need for ...
13h
Zacks Investment Research on MSNWill Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...
Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...
Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...
Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...
Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results